Want to see SE:ASKER full AI Analyst Report?
Top Page
Asker Healthcare Group AB
(ASKER)
Select Model
Select Model
Rating:57Neutral
Price Target:
kr73.00
▼(-11.25% Downside)
Action:Reiterated
Date:09/25/26
The score is supported primarily by solid financial performance—improving profitability and a stronger balance-sheet trend with lower leverage—tempered by weaker cash-flow momentum. However, the overall rating is held back by clearly bearish technical signals (price below key moving averages with negative MACD and weak RSI) and a relatively expensive valuation (high P/E with a low dividend yield).
Positive Factors
Revenue and Profitability Improvement
TTM revenue growth alongside a substantial improvement in net margin indicates stronger earnings conversion as the company expands. This combination provides a better foundation for reinvestment, resilience, and sustained profit development over the next several quarters.
Negative Factors
Weakening Free Cash Flow Momentum
Although free cash flow remains positive, its recent decline signals weaker cash-generation momentum than the company’s earnings trend. If this persists, it could limit internally funded growth, reduce flexibility for investment, and make working-capital demands more consequential.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Improvement
TTM revenue growth alongside a substantial improvement in net margin indicates stronger earnings conversion as the company expands. This combination provides a better foundation for reinvestment, resilience, and sustained profit development over the next several quarters.
Read all positive factors
Asker Healthcare Group AB (ASKER) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr27.13B
Dividend Yield0.55%
Average Volume (3M)704.38K
Price to Earnings (P/E)39.7
Beta (1Y)0.69
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees4,885
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.78
Shares Outstanding383,706,480
10 Day Avg. Volume508,866
30 Day Avg. Volume704,377
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)4.74
Price to Sales (P/S)1.85
P/FCF Ratio42.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.82
Revenue Forecast (FY)kr19.30B
Asker Healthcare Group AB Business Overview & Revenue Model
Company Description
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion s...
Asker Healthcare Group AB Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.01B | 16.79B | 15.03B | 13.45B | 11.72B | 9.35B |
| Gross Profit | 6.98B | 6.05B | 5.88B | 4.52B | 3.78B | 2.61B |
| EBITDA | 2.21B | 2.09B | 1.47B | 1.12B | 1.12B | 835.00M |
| Net Income | 684.00M | 492.00M | 360.00M | 203.00M | 430.00M | 467.00M |
Balance Sheet | ||||||
| Total Assets | 17.83B | 16.77B | 13.12B | 11.33B | 10.23B | 7.36B |
| Cash, Cash Equivalents and Short-Term Investments | 777.00M | 884.00M | 490.00M | 391.00M | 211.00M | 494.00M |
| Total Debt | 6.48B | 5.81B | 5.96B | 4.97B | 4.74B | 3.93B |
| Total Liabilities | 10.81B | 10.19B | 9.62B | 8.29B | 7.44B | 5.54B |
| Stockholders Equity | 6.98B | 6.55B | 3.47B | 3.02B | 2.76B | 1.79B |
Cash Flow | ||||||
| Free Cash Flow | 995.00M | 738.00M | 879.00M | 901.00M | 853.00M | 258.00M |
| Operating Cash Flow | 1.52B | 1.33B | 1.23B | 1.05B | 976.00M | 382.00M |
| Investing Cash Flow | -2.32B | -2.91B | -1.46B | -783.00M | -1.86B | -843.00M |
| Financing Cash Flow | 260.00M | 2.02B | 305.00M | -83.00M | 572.00M | 619.00M |
Asker Healthcare Group AB Technical Analysis
Neutral
82.25
Price Trends
68.30
Positive
73.73
Negative
73.12
Negative
Market Momentum
1.24
Negative
57.04
Neutral
68.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ASKER, the sentiment is Neutral. The current price of 82.25 is above the 20-day moving average (MA) of 68.91, above the 50-day MA of 68.30, and above the 200-day MA of 73.12, indicating a neutral trend. The MACD of 1.24 indicates Negative momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 68.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ASKER.
Asker Healthcare Group AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr42.02B | 44.61 | ― | 0.79% | 5.73% | 90.34% | |
68 Neutral | kr22.11B | 34.47 | 11.32% | 0.83% | 1.62% | 63.45% | |
66 Neutral | kr9.15B | 25.26 | 4.65% | 2.83% | -0.50% | -17.58% | |
61 Neutral | kr15.14B | -3.05 | -61.57% | 0.98% | -1.94% | -1223.74% | |
57 Neutral | kr27.13B | 39.72 | ― | 0.55% | ― | ― | |
57 Neutral | kr21.95B | -60.49 | -4.66% | 3.90% | -6.90% | -232.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
SE:ASKER
Asker Healthcare Group AB
70.70
-12.80
-15.33%
SE:EKTA.B
Elekta AB
59.50
12.53
26.69%
SE:VITR
Vitrolife AB
111.80
-35.48
-24.09%
SE:MCOV.B
Medicover AB
276.50
19.68
7.66%
SE:ALIF.B
AddLife AB
181.30
-21.20
-10.47%
SE:ARJO.B
Arjo AB
33.60
4.24
14.45%
Asker Healthcare Group AB Corporate Events
Asker Healthcare Group Schedules Q3 2026 Report and Webcast
Oct 21, 2026
Asker Healthcare Group will release its interim report for January to September 2026 on 4 November at 08:10 CET, followed by a webcast presentation at 10:00 CET for investors, analysts and media. CEO Johan Falk and CFO Thomas Moss will present and...
Asker Healthcare Group Names Nomination Committee Ahead of 2027 AGM
Sep 18, 2026
Asker Healthcare Group has appointed its Nomination Committee for the 2027 Annual General Meeting, based on the ownership structure as of 31 August 2026, with representatives from Interogo Long-Term Equity, SEB Funds AB, Nordea Funds and the compa...
Asker Healthcare strengthens Polish footprint with acquisition of Labo Clinic
Sep 3, 2026
Asker Healthcare Group has agreed to acquire 100 per cent of Polish distributor Labo Clinic, a specialist in medical equipment, consumables and services for public hospitals and clinics. Labo Clinic holds a market-leading position in neurosurgical...
Asker Healthcare bolsters Norwegian diagnostics offering with Med Kjemi acquisition
Sep 1, 2026
Asker Healthcare Group has expanded its footprint in Norway by acquiring Med Kjemi, a specialist distributor of equipment and consumables for hospital laboratories. Med Kjemi’s portfolio of high-quality products in clinical chemistry, microb...
Asker Healthcare Group Buys Baltic Medtech Firm Ambercell Solutions
Aug 19, 2026
Asker Healthcare Group has acquired 100 per cent of Ambercell Solutions UAB, a leading Baltic medtech solutions provider and distributor active in Lithuania, Latvia, and Estonia. Ambercell specialises in therapy- and procedure-specific packs and m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.